

Press Release

January 20, 2020 | Mumbai

Pain for big pharma as US FDA warnings double

18% of new products to be delayed; strong balance sheets cushion credit metrics

Warning letters issued by the US Food and Drug Administration (FDA) to large Indian pharmaceutical firms¹ more than doubled in the first ten months of calendar 2019 compared with 2018. This will impact about 180 abbreviated new drug applications, or 18% of the total pipeline of large drug makers, delaying new product launches, a CRISIL analysis of current regulatory actions, including adverse observations on FDA audit indicates. The US market accounts for more than a third of overall revenue of the big drug makers or Rs 55,000 crore of sales annually.

Says Sameer Charania, Director, CRISIL Ratings, "With intensifying regulatory scrutiny, sales growth from the US market will drop to 10-11% during fiscals 2020-22, compared with a growth of 16% in fiscal 2019. Large players are banking heavily on successful launch of complex generic products – these filings have risen to about 25% of the overall new product pipeline from nearly zero three years ago. A substantial delay in resolution of regulatory issues and/or heightened scrutiny could derail the US growth story."

A similar trend was noticed in calendar 2015, when FDA scrutiny of Indian drug makers had intensified largely citing data integrity issues by and large. Consequently, US revenue growth had dropped to 6% in fiscal 2017 as new product launches got delayed amid inherent price erosion.

However, the recent FDA observations are relatively less severe and pertain largely to upkeep of facility, cleanliness, and enhanced manufacturing systems. As a result, resolution is expected to be faster.


That said, remediation costs to resolve the regulatory observations are likely to increase for big pharma. This is expected to shave off operating profitability by 100-150 basis points over the next two fiscals from the current 19%. Therefore, cost optimisation and rationalisation of research and development expenses will be critical to arrest further decline in operating profitability of these players.

Says Tanvi Shah, Associate Director, CRISIL Ratings, "The players are, however, taking steps to contain the impact of regulatory scrutiny and moderate its impact on exports to the US. De-risking strategies such as dual-product filings from different plants and transfer of high-value products to unaffected plants through FDA approvals, which reduce the dependence on a single plant may help partially contain the impact."

Besides, steady double-digit domestic sales growth, prudent capital expenditure, and strong balance sheets are expected to help the big pharma companies maintain healthy credit metrics. The debt-to-EBITDA ratio is expected to sustain at 1.6-1.7 times over the medium term.

Annexure

FDA actions on big Indian pharma companies




Source: US FDA; CRISIL

¹ Top 20 companies by revenue (above Rs 1,000 crore)

Glossary of terms

Regulatory alert	Description	Implications
Warning letter	A warning letter notifies the firm that the US FDA considers one or more products, practices, processes, or other activities to be in violation of the Federal Food, Drug, and Cosmetic Act (the Act), its implementing regulations and other federal statutes.	Plant under review-manufacturing not impacted and exports may continue. However, new product approvals are delayed
Import alert	An import alert is a notification from the US FDA to its field staff that all future shipments of the imported product may be refused admission without physical examination of the product in each shipment (called "Detention Without Physical Examination).	Plant under review will face complete ban on exports to the US. No new product approvals from the plant until the issue is resolved.

Revenue growth of big pharma companies



Source: Top 20 company financials and presentations; CRISIL

For further information contact

Media relations	Analytical contacts	Customer service helpdesk
<p>Saman Khan Media Relations CRISIL Limited D: +91 22 3342 3895 M: +91 95 940 60612 B: +91 22 3342 3000 saman.khan@crisil.com</p> <p>Naireen Ahmed Media Relations CRISIL Limited D: +91 22 3342 1818 M: +91 90 040 84769 B: +91 22 3342 3000 naireen.ahmed@crisil.com</p>	<p>Anuj Sethi Senior Director - CRISIL Ratings CRISIL Limited B: +91 44 6656 3100 anuj.sethi@crisil.com</p> <p>Sameer Charania Director - CRISIL Ratings CRISIL Limited D: +91 22 4097 8025 sameer.charania@crisil.com</p>	<p>Timings: 10.00 am to 7.00 pm Toll free Number: 1800 267 1301</p> <p>For a copy of Rationales / Rating Reports: CRISILratingdesk@crisil.com</p> <p>For Analytical queries: ratingsinvestordesk@crisil.com</p>

About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India's foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers.

We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: [LINKEDIN](#) | [TWITTER](#) | [YOUTUBE](#) | [FACEBOOK](#)

About CRISIL Ratings

CRISIL Ratings is part of CRISIL Limited ("CRISIL"). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI"). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 110,000 MSMEs have been rated by us.

CRISIL PRIVACY

CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.

DISCLAIMER

This Press Release is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The Press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its Press Releases for consideration or otherwise through any media including websites, portals etc.

CRISIL has taken due care and caution in preparing this Press Release. Information has been obtained by CRISIL from sources which it considers reliable. However, CRISIL does not guarantee the accuracy, adequacy or completeness of information on which this Press Release is based and is not responsible for any errors or omissions or for the results obtained from the use of this Press Release. CRISIL, especially states that it has no financial liability whatsoever to the subscribers/ users/ transmitters/ distributors of this Press Release. CRISIL or its associates may have other commercial transactions with the company/entity.